Physician profile
Mark B Chaplick
NPI 1316928179
$4,286.92
in general payments reported to CMS, 2019-2025
47 companies · $439 in 2025
The $439 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,802 · 2020: $525 · 2021: $109 · 2022: $294 · 2023: $570 · 2024: $547 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,555.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $579.40 | 2019-2024 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $511.88 | 2019-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $415.40 | 2019-2025 | Xtampza, Belbuca |
| Scilex Pharmaceuticals INC. | $287.64 | 2019-2024 | Ztlido |
| Boston Scientific Corporation | $238.73 | 2019-2025 | Wavewriter Alpha Prime 16, Superion Indirect Decompression System, General - Therapies |
| Horizon Therapeutics Plc | $225.25 | 2019-2022 | |
| Amgen INC. | $192.62 | 2019-2020 | |
| Globus Medical, INC. | $167.14 | 2025 | Senza, Vyrsa V1 |
| Pfizer INC. | $162.31 | 2019-2020 | |
| Biodelivery Sciences International, INC. | $150.89 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $144.94 | 2019-2022 | |
| Abbvie INC. | $79.90 | 2022-2024 | Ubrelvy |
| Medtronic USA, INC. | $76.64 | 2019-2020 | |
| Grt US Holding, INC. | $70.22 | 2020-2022 | |
| Si-Bone, INC. | $68.10 | 2023-2024 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $62.88 | 2022-2023 | Tirosint, Licart |
| Vertex Pharmaceuticals Incorporated | $61.17 | 2024-2025 | |
| Sentynl Therapeutics, INC. | $60.62 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $56.33 | 2019 | |
| Spr Therapeutics, INC | $47.80 | 2023 | Sprint Pns System |
| Medtronic, INC. | $46.53 | 2024-2025 | Intellis Adaptivestim, Inceptiv |
| Saluda Medical Americas, INC. | $41.66 | 2022 | |
| Allergan, INC. | $37.52 | 2019 | |
| Protega Pharmaceutials INC | $37.34 | 2024 | Roxybond |
| Electronic Waveform Lab, INC. | $36.03 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $34.88 | 2025 | Purified Cortrophin Gel |
| Tersera Therapeutics LLC | $33.81 | 2019-2025 | Prialt |
| Daiichi Sankyo INC. | $31.83 | 2019 | |
| Nalu Medical, INC. | $31.64 | 2024 | Nalu Neurostimulation System |
| Biotissue Holdings INC. | $29.84 | 2023 | |
| Alnylam Pharmaceuticals INC. | $21.01 | 2024 | Amvuttra |
| Biotronik Nro, INC. | $20.00 | 2025 | Prospera |
| Hikma Pharmaceuticals USA | $19.13 | 2023 | Kloxxado |
| Fidia Pharma USA INC. | $17.71 | 2025 | Hymhyn |
| Almatica Pharma LLC | $17.04 | 2022 | |
| Curonix LLC | $16.78 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Forte Bio-Pharma LLC | $16.43 | 2025 | Prolate, Tanlor, Nalocet |
| Shionogi INC | $16.11 | 2019 | |
| Tonix Medicines, INC. | $15.20 | 2025 | Tonmya |
| Assertio Therapeutics, INC. | $15.20 | 2019 | |
| Kyowa Kirin, INC. | $14.25 | 2024 | Crysvita |
| Bioventus LLC | $13.79 | 2025 | Xcell |
| Convatec INC. | $13.58 | 2024 | |
| Vertical Pharmaceuticals, LLC | $13.30 | 2019 | |
| Lilly USA, LLC | $13.11 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.13 | 2022 | |
| Novartis Pharmaceuticals Corporation | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Chaplick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.